Department of Integrated Chinese and Western Medicine, Zhangye People's Hospital affiliated to Hexi University, Gansu, China.
Department of Traditional Chinese Medicine, Zhangye People's Hospital affiliated to Hexi University, Gansu, China.
Medicine (Baltimore). 2022 Nov 11;101(45):e31736. doi: 10.1097/MD.0000000000031736.
Ischemic heart disease is the main cause of heart failure, which seriously endangers the health of people and puts a huge burden on health care resources all over the world. We propose the current protocol to evaluate the effectiveness and safety of Rhodiola on ischemic heart disease, providing a reference for clinical use.
Two research members will electronically and independently search 4 English databases (EMBASE, PubMed, National Guideline Clearinghouse, and Cochrane Central Register of Controlled Trials) and 4 Chinese databases (Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, Wanfang Database, and VIP Database) from their inception to October 2020. Quality assessment of the included randomized controlled trial was assessed using the Cochrane Collaboration's tool. All calculations were carried out with Stata 11.0 (The Cochrane Collaboration, Oxford, United Kingdom).
A synthesis of current evidence of Rhodiola formulation for ischemic heart disease will be provided in this protocol.
This study will provide a theoretical basis for the clinical use of Rhodiola formulation for treating ischemic heart disease.
缺血性心脏病是心力衰竭的主要病因，严重危害着人们的健康，给全球的医疗资源带来了巨大的负担。我们提出了目前的方案来评估红景天制剂治疗缺血性心脏病的有效性和安全性，为临床应用提供参考。
两名研究人员将从建库起至 2020 年 10 月，分别独立地通过电子检索 4 个英文数据库（EMBASE、PubMed、国家指南库和 Cochrane 对照试验中心注册库）和 4 个中文数据库（中国生物医学文献数据库、中国知网、万方数据库和维普数据库），评价纳入的随机对照试验的质量使用 Cochrane 协作网的工具进行。所有的计算均使用 Stata 11.0（The Cochrane Collaboration，牛津，英国）完成。
本方案将对红景天制剂治疗缺血性心脏病的现有证据进行综合。
本研究将为红景天制剂治疗缺血性心脏病的临床应用提供理论依据。
